Dana Materia
Nurse Practitioner · Staten Island, NYNPI 1740263839
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 592 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 592 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Bayer$935
- AbbVie$788
- Mannkind Corporation$680
- AstraZeneca$679
- plus $5K from 36 others
What the payments were for
- Food & beverage$11,417100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 120 | $2,142 |
| Lilly USA, LLC | 79 | $1,487 |
| Bayer | 49 | $935 |
| AbbVie | 43 | $788 |
| Mannkind Corporation | 35 | $680 |
| AstraZeneca | 35 | $679 |
| Amgen | 30 | $593 |
| Abbott | 25 | $586 |
| Boehringer Ingelheim | 26 | $562 |
| Sanofi-aventis U.S. LLC | 28 | $533 |
| Radius Health, Inc. | 18 | $476 |
| Xeris Pharmaceuticals, Inc. | 11 | $216 |
| Esperion Therapeutics, Inc. | 13 | $185 |
| Amneal Pharmaceuticals LLC | 8 | $163 |
| Dexcom, Inc. | 8 | $153 |
| Johnson & Johnson | 6 | $114 |
| Chiesi USA, Inc. | 4 | $96 |
| Embecta Corp. | 4 | $85 |
| Merck | 5 | $78 |
| Corcept Therapeutics | 4 | $77 |
| IBSA Pharma Inc. | 4 | $68 |
| Insulet Corporation | 3 | $66 |
| Kyowa Kirin, Inc. | 3 | $61 |
| Pfizer | 3 | $61 |
| GSK | 2 | $55 |
| Madrigal Pharmaceuticals | 2 | $51 |
| Tolmar, Inc. | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Medtronic | 2 | $41 |
| BD | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| Intuity Medical Inc | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Bausch Health US, LLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Lifescan, Inc. | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Cequr Corporation | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,417 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 383 | $658,663 |
| MounjaroTirzepatide | 262 | $482,015 |
| TrulicityDulaglutide | 191 | $303,660 |
| JardianceEmpagliflozin | 129 | $183,324 |
| FarxigaDapagliflozin Propanediol | 73 | $109,007 |
| Tresiba Flextouch U-200Insulin Degludec | 95 | $94,594 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $61,504 |
| SynjardyEmpagliflozin/Metformin Hcl | 34 | $48,544 |
| RybelsusSemaglutide | 27 | $39,828 |
| JanuviaSitagliptin Phosphate | 25 | $39,392 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $32,835 |
| Xigduo XrDapaglifloz Propaned/Metformin | 27 | $31,394 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $27,584 |
| ProliaDenosumab | 14 | $24,923 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $22,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,487 | $785,675453 claims |
| Novo NordiskOzempic, Rybelsus | $2,142 | $698,491410 claims |
| Boehringer IngelheimJardiance, Synjardy, Trijardy Xr, Tradjenta, Synjardy Xr | $562 | $282,867205 claims |
| AstraZenecaFarxiga | $679 | $109,00773 claims |
| MerckJanuvia | $78 | $39,39225 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $533 | $32,83520 claims |
| AmgenProlia | $593 | $24,92314 claims |
| Mannkind CorporationAfrezza | $680 | $18,51611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $163 | $2,003193 claims |
| AbbVieSynthroid | $788 | $1,56731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Staten Island
- Alla AdlerStaten Island$12K
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.